Phase Forward Introduces Phase Forward(TM) IRT 5.0 Interactive Response Technology Solution

Phase Forward Introduces Phase Forward(TM) IRT 5.0 Interactive Response Technology Solution

Major New Release Offers Proactive Clinical Supply Management Tools; Designed to Provide Increased Confidence in Trial Supply Availability

WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 22, 2009-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a major new release of its Interactive Response Technology (IRT) solution, Phase ForwardTM IRT 5.0. Based on best-in-breed technology gained in the company's September 2008 acquisition of Clarix, Phase Forward IRT 5.0 gives managers direct control over clinical supply management and helps to provide assurance of supply availability at randomization. Phase Forward IRT also offers a new integrated drug forecasting module for advanced global clinical trial supply management and a new, enhanced user interface to streamline navigation and consolidate workflow.

"Phase Forward IRT 5.0 is a major step forward in helping customers leverage the power of IRT technology to improve efficiency within clinical trial supply management and planning, a crucial factor in every trial's success," said Steve Rosenberg, senior vice president of products and services, Phase Forward. "This release is a key component of our integrated clinical research suite for end-to-end clinical trial management."

The Phase Forward IRT 5.0 release introduces a new "smart system intelligence" feature that puts clinical supply managers in control, helping them effectively respond to sudden increases in new subjects at any point in the trial. On the basis of user-defined variables, the application will either automatically generate a supply order or notify the supply manager of a potential stock-out, ensuring that subject enrollment is not compromised by lack of study supplies.

The new integrated drug forecasting module gives managers pre-study planning tools to optimize trial supply strategies. During live trials the application links to trial data on demand, enabling managers to quickly compare planning assumptions and forecasts with actual trial data, update supply demand assumptions as needed and modify manufacturing schedules to respond to new projections.

New user interface and dashboard views provide at-a-glance access to critical information, visual status alerts and filtering capabilities to guide users intuitively through tasks, consolidating workflow and helping to ensure that the most pertinent information stays paramount. The release also provides multilingual capabilities, including Japanese, to enable use across the global trial community.

Together, Phase Forward's IRT and InFormTM GTM electronic data capture (EDC) solutions offer users a tightly integrated solution with a single, unified interface and seamless workflow, providing the total cost of ownership and single point of contact benefits inherent in a single vendor solution.

The Phase Forward IRT 5.0 solution and the optional forecasting module are immediately available.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and acceptance of Phase Forward's products, features of Phase Forward products that are not believed to be available in competing products, and the benefits to customers from the use of such products. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, Phase Forward's inability to convince current and potential customers to order its products, the failure of customers to realize benefits from the use of these products, changes in industry standards, changes in the manner in which Phase Forward customers conduct business, and changes in or introduction of competitive products. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.